• Integration of a recent infection testing algorithm into HIV surveillance in Ireland: improving HIV knowledge to target prevention

      Robinson, E; Moran, J; O'Donnell, K; Hassan, J; Tuite, H; Ennis, O; Cooney, F; Nugent, E; Preston, L; O'Dea, S; Doyle, S; Keating, S; Connell, J; De Gascun, C; Igoe, D (Epidemiology and Infection, 2019-02)
    • Drug-related bloodborne viruses in Ireland 2018

      Health Protection Surveillance Centre (HSE Health Protection Surveillance Centre, 2018-09-18)
    • Drug-related bloodborne viruses in Ireland 2018

      Health Protection Surveillance Centre; Health Service Executive (HSE) (Health Service Executive (HSE), 2018-09)
    • Audit of hepatitis C testing and referral in addiction treatment centres in CHO Area 7

      Murphy, Niamh; Thornton, Lelia; Bourke, Margaret; Health Protection Surveillance Centre (2018-02)
    • National Guidelines for the Prevention of Nosocomial Aspergillosis

      Aspergillosis Subcommittee of the Health Protection Surveillance Centre Scientific Advisory Committee (Health Protection Surveillance Centre, 2018-01)
    • Report of the National Perinatal Hepatitis B Prevention Programme November 2017

      National Perinatal Hepatitis B Prevention Programme Working Group (2017-11-14)
    • Hepatitis C virus seroprevalence and prevalence of chronic infection in the adult population in Ireland: a study of residual sera, April 2014 to February 2016

      Garvey, P; O’Grady, B; Franzoni, G; Bolger, M; Crosby, K Irwin; Connell, J; Burke, D; De Gascun, C; Thornton, L (Eurosurveillance, 2017-07)
    • Knowledge of HIV PEP Among Healthcare Workers in Ireland, 2016: Room for Improvement

      Garvey, P; Thornton, L; Lyons, F (Irish Medical Journal, 2017-01)
    • Reporting of acute flaccid paralysis in children under 15 years of age: improving surveillance, January 2009 – December 2014

      Flanagan, P; O’Lorcain, P; Cotter, S; Connell, J; Lynch, B; Cunney, R; O’Flanagan, D (Irish Medical Journal, 2016-02)
    • Audit of hepatitis C testing and referral: Addiction Treatment Centres Community Health Organisation Area 7

      Bourke, Margaret; Hennessy, Sarah; Thornton, Lelia; Addiction Treatment Clinical Governance Committee; HPSC (2015-11-09)
    • Injection of new psychoactive substance snow blow associated with recently acquired HIV infections among homeless people who inject drugs in Dublin, Ireland, 2015.

      Giese, Coralie; Igoe, Derval; Gibbons, Zorina; Hurley, Caroline; Stokes, Siobhan; McNamara, Sinead; Ennis, Orla; O'Donnell, Kate; Keenan, Eamon; De Gascun, Cillian; Lyons, Fiona; Ward, Mary; Danis, Kostas; Glynn, Ronan; Waters, Allison; Fitzgerald, Margaret (Euro surveillance : bulletin Européen sur les maladies transmissibles = European communicable disease bulletin, 2015-10-08)
      In February 2015, an outbreak of recently acquired HIV infections among people who inject drugs (PWID) was identified in Dublin, following similar outbreaks in Greece and Romania in 2011. We compared drug and risk behaviours among 15 HIV cases and 39 controls. Injecting a synthetic cathinone, snow blow, was associated with recent HIV infection (AOR: 49; p = 0.003). Prevention and control efforts are underway among PWID in Dublin, but may also be needed elsewhere in Europe.
    • Adult immunisations

      O'Flanagan, D (Nursing in General Practice, 2015-09)
    • Guidelines for the prevention and control of infection from water systems in healthcare facilities

      Health Protection Surveillance Centre (HSE Health Protection Surveillance Centre (HPSC), 2015-08-12)
    • The European I-MOVE Multicentre 2013-2014 Case-Control Study. Homogeneous moderate influenza vaccine effectiveness against A(H1N1)pdm09 and heterogenous results by country against A(H3N2).

      Valenciano, Marta; Kissling, Esther; Reuss, Annicka; Jiménez-Jorge, Silvia; Horváth, Judit K; Donnell, Joan M O; Pitigoi, Daniela; Machado, Ausenda; Pozo, Francisco; 1Epidemiology Department, EpiConcept, Paris, France. Electronic address: m.valenciano@epiconcept.fr. 2Epidemiology Department, EpiConcept, Paris, France. 3Department for Infectious Disease Epidemiology Respiratory Infections Unit, Robert Koch Institute, Berlin, Germany. 4National Centre of Epidemiology/CIBER Epidemiología y Salud Pública (CIBERESP), Institute of Health Carlos III, Madrid, Spain. 5Department of Public Health, Strategic Planning and Epidemiology, Office of the Chief Medical Officer, Budapest, Hungary. 6Health Protection Surveillance Centre, Dublin, Ireland. 7UMF Carol Davila, INCDMI Cantacuzino, Bucharest, Romania. 8Department of Epidemiology, National Institute of Health Dr. Ricardo Jorge, Lisbon, Portugal. 9National Centre for Microbiology, National Influenza Centre-Institute of Health Carlos III, Madrid, Spain. (2015-06-04)
      The results suggest a moderate 2013-2014 influenza VE against A(H1N1)pdm09 and a low VE against A(H3N2). The A(H3N2) estimates were heterogeneous among study sites. Larger sample sizes by study site are needed to prevent statistical heterogeneity, decrease variability and allow for two-stage pooled VE for all subgroup analyses.
    • Influenza surveillance in Europe. Comparing intensity levels calculated using the Moving Epidemic Method.

      Vega, Tomás; Lozano, José; Meerhoff, Tamara; Snacken, René; Beauté, Julien; Jorgensen, Pernille; Ortiz de Lejarazu, Raúl; Domegan, Lisa; Mossong, Joël; Nielsen, Jens; Born, Rita; Larrauri, Amparo; Brown, Caroline (2015-05-30)
      Epidemic and intensity thresholds varied by country. ILI and ARI levels normalized by MEM in 2013/2014 showed that the intensity of the season in Europe was between low and medium in most of the countries. Comparing intensity among seasons or countries is essential for understanding patterns in seasonal epidemics. An automated standardized model for comparison should be implemented at national and international levels. This article is protected by copyright. All rights reserved.
    • Towards tuberculosis elimination: an action framework for low-incidence countries.

      Lönnroth, Knut; Migliori, Giovanni Battista; Abubakar, Ibrahim; D'Ambrosio, Lia; de Vries, Gerard; Diel, Roland; Douglas, Paul; Falzon, Dennis; Gaudreau, Marc-Andre; Goletti, Delia; González Ochoa, Edilberto R; LoBue, Philip; Matteelli, Alberto; Njoo, Howard; Solovic, Ivan; Story, Alistair; Tayeb, Tamara; van der Werf, Marieke J; Weil, Diana; Zellweger, Jean-Pierre; Abdel Aziz, Mohamed; Al Lawati, Mohamed R M; Aliberti, Stefano; Arrazola de Oñate, Wouter; Barreira, Draurio; Bhatia, Vineet; Blasi, Francesco; Bloom, Amy; Bruchfeld, Judith; Castelli, Francesco; Centis, Rosella; Chemtob, Daniel; Cirillo, Daniela M; Colorado, Alberto; Dadu, Andrei; Dahle, Ulf R; De Paoli, Laura; Dias, Hannah M; Duarte, Raquel; Fattorini, Lanfranco; Gaga, Mina; Getahun, Haileyesus; Glaziou, Philippe; Goguadze, Lasha; Del Granado, Mirtha; Haas, Walter; Järvinen, Asko; Kwon, Geun-Yong; Mosca, Davide; Nahid, Payam; Nishikiori, Nobuyuki; Noguer, Isabel; O'Donnell, Joan; Pace-Asciak, Analita; Pompa, Maria G; Popescu, Gilda G; Robalo Cordeiro, Carlos; Rønning, Karin; Ruhwald, Morten; Sculier, Jean-Paul; Simunović, Aleksandar; Smith-Palmer, Alison; Sotgiu, Giovanni; Sulis, Giorgia; Torres-Duque, Carlos A; Umeki, Kazunori; Uplekar, Mukund; van Weezenbeek, Catharina; Vasankari, Tuula; Vitillo, Robert J; Voniatis, Constantia; Wanlin, Maryse; Raviglione, Mario C; 1Global TB Programme, World Health Organization, Geneva, Switzerland Both authors contributed equally. 2WHO Collaborating Centre for Tuberculosis and Lung Diseases, Fondazione S. Maugeri, IRCCS, Tradate, Italy Both authors contributed equally. 3TB Section, University College London and Public Health England, London, UK. 4WHO Collaborating Centre for Tuberculosis and Lung Diseases, Fondazione S. Maugeri, IRCCS, Tradate, Italy. 5KNCV Tuberculosis Foundation, The Hague, The Netherlands. 6University Hospital Schleswig Holstein, Institute for Epidemiology, Kiel, Germany. 7Global Health Borders Refugee and Onshore Services, Dept of Immigration and Border Protection, Sydney, Australia. 8Global TB Programme, World Health Organization, Geneva, Switzerland. 9Centre for Communicable Diseases and Infection Control, Public Health Agency of Canada, Montreal, QC, Canada. 10National Institute for Infectious Diseases, Rome, Italy. 11Research and Surveillance Group on TB, Leprosy and ARI, Epidemiology Board, Institute of Tropical Medicine "Pedro Kourí", Havana, Cuba. 12Division of TB Elimination, Centers for Disease Control and Prevention, Atlanta, GA, USA. 13TB Dept, National Institute for TB, Respiratory Diseases and Thoracic Surgery, Vysne Hagy, Catholic University, Ružomberok, Slovakia. 14Find and Treat, London, UK. 15National TB Control Programme, Ministry of Health, Riyadh, Saudi Arabia. 16European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden. 17Swiss Lung Association, Bern, Switzerland. 18WHO Regional Office for the Eastern Mediterranean, Cairo, Egypt. 19Ministry of Health, Muscat, Oman. 20Università degli Studi di Milano - Bicocca, UO Clinica Pneumologica, AO San Gerardo, Monza, Italy. 21Belgian Lung and Tuberculosis Association, Brussels, Belgium. 22Ministry of Health, Brasilia, Brazil. 23Dipartimento Fisiopatologia Medico-Chirurgica e dei Trapianti, University of Milan, IRCCS Fondazione Cà Granda, Milan, Italy. 24US Agency for International Development, Washington, DC, USA. 25Unit of Infectious Diseases, Institution of Medicine, Karolinska Institute Solna and Karolinska University Hospital, Stockholm, Sweden. 26University of Brescia, Brescia, Italy. 27Ministry of Health, Jerusalem, Israel. 28IRCCS San Raffaele Scientific Institute, Milan, Italy. 29Advocates for Health International, San Diego, CA, USA. 30TB and M/XDR-TB Control Programme, WHO Regional Office for Europe, Copenhagen, Denmark. 31Norwegian Institute of Public Health, Oslo, Norway. 32Médecins sans Frontières, Rome, Italy. 33General Directorate of Health, Lisbon, Portugal. 34Istituto Superiore di Sanita, Rome, Italy. 35National Referral Centre for Mycobacteria, Athens Chest Hospital, Ministry of Health, Athens, Greece. 36International Federation of Red Cross and Red Crescent Societies, Geneva, Switzerland. 37WHO Regional Office for the Americas, Washington, DC, USA. 38Dept of Infectious Disease Epidemiology, Robert Koch Institute, Berlin, Germany. 39Finnish Lung Health Association, Helsinki, Finland Helsinki University Central Hospital, Division of Infectious Diseases, Helsinki, Finland. 40Korea Centers for Disease Control and Prevention (KCDC), Ministry of Health and Welfare, Seoul, Republic of Korea. 41International Organization for Migration, Geneva, Switzerland. 42University of California, San Francisco, CA, USA American Thoracic Society (ATS), New York, NY, USA. 43Stop TB and Leprosy Elimination, WHO Regional Office for the Western Pacific, Manila, Philippines. 44Instituto de Salud Carlos III, Madrid, Spain. 45HSE Health Protection Surveillance Centre, Dublin, Ireland. 46Ministry for Health, Valletta, Malta. 47Ministry of Health, Rome, Italy. 48Pneumology Institute Marius Nasta, Bucharest, Romania. 49Coimbra University Hospital, Coimbra, Portugal. 50Statens Serum Institut (SSI), Copenhagen, Denmark. 51Institut Jules Bordet (ULB), Brussels, Belgium. 52Croatian National Institute of Public Health, Zagreb, Croatia. 53Health Protection Scotland, Glasgow, UK. 54Clinical Epidemiology and Medical Statistics Unit, Dept of Biomedical Sciences, University of Sassari, Research, Medical Education and Professional Development Unit, AOU Sassari, Sassari, Italy. 55Asociacion Latinoamericana de Torax (ALAT) - Fundacion Neumologica Colombiana, Bogota, Colombia. 56Ministry of Health, Labour and Welfare, Tokyo, Japan. 57Finnish Lung Health Association, Helsinki, Finland. 58Caritas Internationalis, Geneva, Switzerland. 59Ministry of Health, Nicosia, Cyprus. 60Fonds des Affections Respiratoires (FARES), Brussels, Belgium. (ERS Journals, 2015-04)
      This paper describes an action framework for countries with low tuberculosis (TB) incidence (<100 TB cases per million population) that are striving for TB elimination. The framework sets out priority interventions required for these countries to progress first towards "pre-elimination" (<10 cases per million) and eventually the elimination of TB as a public health problem (less than one case per million). TB epidemiology in most low-incidence countries is characterised by a low rate of transmission in the general population, occasional outbreaks, a majority of TB cases generated from progression of latent TB infection (LTBI) rather than local transmission, concentration to certain vulnerable and hard-to-reach risk groups, and challenges posed by cross-border migration. Common health system challenges are that political commitment, funding, clinical expertise and general awareness of TB diminishes as TB incidence falls. The framework presents a tailored response to these challenges, grouped into eight priority action areas: 1) ensure political commitment, funding and stewardship for planning and essential services; 2) address the most vulnerable and hard-to-reach groups; 3) address special needs of migrants and cross-border issues; 4) undertake screening for active TB and LTBI in TB contacts and selected high-risk groups, and provide appropriate treatment; 5) optimise the prevention and care of drug-resistant TB; 6) ensure continued surveillance, programme monitoring and evaluation and case-based data management; 7) invest in research and new tools; and 8) support global TB prevention, care and control. The overall approach needs to be multisectorial, focusing on equitable access to high-quality diagnosis and care, and on addressing the social determinants of TB. Because of increasing globalisation and population mobility, the response needs to have both national and global dimensions.
    • Outbreak of hepatitis A infection associated with the consumption of frozen berries, Ireland, 2013 - linked to an international outbreak.

      Fitzgerald, M; Thornton, L; O'Gorman, J; O Connor, L; Garvey, P; Boland, M; Part, Am; Rogalska, J; Coughlan, H; MacDiarmada, J; Heslin, J; Canny, M; Finnegan, P; Moran, J; O Flanagan, D; Health Service Executive (HSE) - Health Protection Surveillance Centre (HPSC), Dublin, Ireland. (Eurosurveillance : bulletin Européen sur les maladies transmissibles, 2014-10-30)
    • Describing readmissions to an Ebola case management centre (CMC), Sierra Leone, 2014.

      Fitzpatrick, G; Vogt, F; Moi Gbabai, Ob; Black, B; Santantonio, M; Folkesson, E; Decroo, T; Van Herp, M; Medecins Sans Frontieres, Dublin, Ireland. (European Centre for Disease Control, 2014-10)